Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

PHASE3CompletedINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

September 30, 2011

Study Completion Date

November 30, 2011

Conditions
Lung Transplant
Interventions
DRUG

Cyclosporine Inhalation Solution (CIS)

Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)

Trial Locations (19)

10032

New York Presbyterian Hospital, Columbia University Med. Ctr., New York

15213

University of Pittsburgh Medical Center, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

21201

University of Maryland, Baltimore

22402

Inova Fairfax Hospital, Falls Church

32224

Mayo Clinic, Jacksonville

32610

University of Florida Health Sciences Center, Gainesville

33601

Tampa General Hospital, Tampa

44195

Cleveland Clinic, Cleveland

46202

Indiana Methodist Research Institute, Indianapolis

55455

University of Minnesota, Minneapolis

60153

Loyola University Hospital, Maywood

60637

University of Chicago Hospitals, Chicago

77030

Baylor College of Medicine, Houston

80262

University of Colorado Health Sciences Center, Denver

90095

UCLA School of Medicine, Los Angeles

94143

University of California, San Francisco, San Francisco

94305

Stanford University Medical Center, Stanford

M5G 2N2

University of Toronto, Toronto

Sponsors
All Listed Sponsors
lead

APT Pharmaceuticals, Inc.

INDUSTRY